[Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].

To evaluate the efficacy and long-term outcome of a combined protocol for multiple myeloma (MM) , including induction therapy, autologous hematopoietic stem cell transplantation (ASCT) and consolidation and maintenance therapy. Clinical records of 144 patients with MM from January 1, 2005 to February 1, 2016 were retrospectively analyzed. The overall response rate (ORR) after ASCT was 100.0%, in which the complete remission (CR) was 64.1% and the best treatment response rate of superior to PR was 89.4%. During a median follow-up of 47 months, patients with an overall survival (OS) and progression free survival (PFS) was 120.9 and 56.9 months respectively. 5y-OS (73.7±4.7) %, 7y-OS (60.5±6.3) %; 3y-PFS (69.2±4.2) %, 5y-PFS (47.8±5.3) %. The median OS and PFS between the first line transplantation group and salvage transplantation group were 120.9 months 50.1 months and 60.2 months 16.7 months (all =0.000). In 127 patients with R-ISS staging, the median survival of Ⅰ, Ⅱ, Ⅲ stage was 120.9 months (=43) , 88.4 months (=64) , 35.6 months (=20) , respectively (=0.000). For subgroup analysis of survival in early and late ASCT, the median OS of patients with R-ISS stage Ⅲ (35.6 months 15.8 months, =0.031) and the median PFS of two groups (phase Ⅰ: 72.1 months 18.9 months, =0.000; Ⅱ: 53.4 months 16.7 months, =0.012; Ⅲ: 28.5 months 5.9 months, =0.001) were different. Multivariate analysis showed that only R-ISS and the degree of remission before transplantation had impact on OS (=8.486, 95% 2.549-28.255, =0.003) and PFS (=2.412, 95% 1.364-4.266, =0.002) , respectively. The combined protocol containing ASCT is effective for MM patients, improving remission rate and remission depth, prolonging PFS and OS. First line transplantation could significantly prolong the OS and PFS as compared with salvage transplantation. R-ISS and pre-transplantation remission depth are prognostic factors for survival.